Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan cilexetil vs standard therapy on BNP levels in chronic heart failure
2005-001306-87Phase 3Terminated
- Sponsor
- Takeda
- Start
- Feb 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of candesartan in chronic heart failure (CHF) and left ventricular failure (LVF) (2 arms), sponsored by Takeda. Primary endpoint: Serum brain natriuretic peptide (BNP) levels. Started Feb 2007; status: terminated.
02
Drugs
candesartan
03
Conditions
chronic heart failure (CHF)left ventricular failure (LVF)
Beyond the preview
Go deeper on 2005-001306-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001306-87.